FIELD: medicine; pharmacology.
SUBSTANCE: invention can be applied in treatment of repeated hypertension with serum hyperuricemia and/or hypercholesteremia, with 2-propyl-3-{[2'-(1H-tetrasol-5-yl)biphenyl-4-yl]methyl}-5,6,7,8-tetrahydrocycloheptaimidasol-4-(3H)-on or 2-propyl-3-{[2'-(1H-tetrasol-5-yl)biphenyl-4-yl]methyl} -5,6,7,8-tetrahydrocycloheptaimidasol-4-(3H)-on together with diuretics or hypolipidemic drugs as effector.
EFFECT: enhanced efficiency of treatment.
6 cl, 2 dwg, 7 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICINAL AGENT FOR TREATMENT OF HYPERTENSION OR HIGH BLOOD PRESSURE | 2010 |
|
RU2539382C2 |
| PHARMACEUTICAL COMPOSITION INCLUDING SELECTIVE AGONIST OF IMIDAZOLINE RECEPTOR I1 AND BLOCKER OF ANGIOTENSIN II RECEPTOR | 2004 |
|
RU2362561C2 |
| METHOD OF TREATMENT OF ISOLATED SYSTOLIC ARTERIAL HYPERTENSION OF 1 DEGREE IN PATIENTS IN EARLY PERIOD OF OLD AND SENILE AGE | 2019 |
|
RU2726071C1 |
| METHOD DETERMINING TACTICS OF CARRYING OUT OF MEDICAL ACTIONS AT PATIENTS WITH METABOLIC SYNDROME AGAINST ARTERIAL HYPERTENSIA | 2007 |
|
RU2337612C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR AND ACE INHIBITOR | 2016 |
|
RU2750934C2 |
| COMBINATION OF DIPEPTIDILPEPTIDASE IV (DPP IV) INHIBITOR AND CARDIOVASCULAR SUBSTANCE | 2003 |
|
RU2336876C2 |
| PHARMACEUTICAL COMBINATIONS OF ANGIOTENSIN RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2503668C2 |
| PHARMACEUTICAL COMPOSITION INCLUDING RENIN INHIBITOR, CALCIUM CHANNEL BLOCKER AND DIURETIC | 2003 |
|
RU2316318C2 |
| METHOD FOR THERAPY OF ARTERIAL PRESSURE IN OBESE CHILDREN BASED ON THE STUDY OF PATHOLOGICAL GENE ALLELES | 2022 |
|
RU2787390C1 |
| PHARMACEUTICAL COMBINATIONS OF ANGIOTENSINE RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2459809C2 |
